Trial Profile

ULACNet 102: Probiotics to Treat HSIL and Reduce Persistent High Risk HPV Infection in Women and Men Living With HIV

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EXE-346 (Primary)
Indications Anal intraepithelial neoplasia
Focus Adverse reactions; Therapeutic Use
Acronyms ProtecT; ULACNet102

Most Recent Events

02 Feb 2026 Planned End Date changed from 1 Oct 2026 to 31 Dec 2026.
02 Feb 2026 Planned primary completion date changed from 31 Oct 2026 to 31 Dec 2026.
02 Feb 2026 Planned initiation date changed from 1 Dec 2025 to 15 Mar 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com